EVAX
$3.91-0.09 (-2.25%)
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-b...
Recent News
European Equities Traded in the US as American Depositary Receipts Higher Monday
European equities traded in the US as American depositary receipts were rising on Monday morning, up
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in US as ADRs Slump in Thursday Trading
European equities traded in the US as American depositary receipts slumped late Thursday morning wit
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
Evaxion AS (EVAX) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial Resilience
Evaxion AS (EVAX) showcases financial growth and strategic advancements, extending its cash runway and enhancing its AI-Immunology platform's potential.